ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
Globe Newswire (Tue, 8-Sep 4:30 PM ET)
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Mon, 17-Aug 4:30 PM ET)
ImageneBio Reports Second Quarter 2026 Financial Results
Globe Newswire (Wed, 5-Aug 8:00 AM ET)
ImageneBio Appoints Matt Robbins as General Counsel
Globe Newswire (Tue, 7-Jul 7:00 AM ET)
ImageneBio Secures $30 Million Private Placement to Accelerate Development of Lead Program IMG-007
Market Chameleon (Mon, 13-Apr 6:46 AM ET)
ImageneBio Secures $30 Million in Private Funding to Advance Promising OX40 Antagonist IMG-007
Market Chameleon (Mon, 13-Apr 4:25 AM ET)
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
Imagenebio trades on the NASDAQ stock market under the symbol IMA.
As of October 1, 2026, IMA stock price climbed to $4.60 with 168 million shares trading.
IMA has a market cap of $52.22 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that IMA belongs to (by Net Assets): VTI, VXF, IWC.
IMA has underperformed the market in the last year with a price return of -43.6% while the SPY ETF gained +15.2%. IMA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.0% and -6.7%, respectively, while the SPY returned +2.0% and +1.0%, respectively.
IMA support price is $4.33 and resistance is $4.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMA shares will trade within this expected range on the day.
